Chris Storgard, M.D. joined ADARx in April 2024 as our Chief Medical Officer, with over 25 years of clinical research experience securing multiple global drug approvals across various therapeutic areas. Prior to ADARx, Dr. Storgard was Chief Medical Officer at Heron Therapeutics, Inc. and Fate Therapeutics, Inc. His earlier roles include Vice President at Ardea Biosciences, an AstraZeneca Company, as well as leadership positions at Biogen-Idec Ltd. and Amgen Inc.. Dr. Storgard received his MD degree and completed an Internal Medicine residency at the University of Saskatchewan, Canada. Following a Rheumatology fellowship at the Scripps Clinic and Research Institute in San Diego, CA, he served as a Senior Associate Consultant in the Division of Rheumatology, Mayo Clinic, Rochester, MN and as an Assistant Professor and Member of the Molecular Medicine Program at the Mayo School of Medicine.
